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Abstract. The small, calcium-sensor protein, calmodulin, is ubiquitously expressed and central to cell function in all cell types.
Here the literature linking calmodulin to Alzheimer’s disease is reviewed. Several experimentally-verified calmodulin-binding
proteins are involved in the formation of amyloid- plaques including amyloid- protein precursor, -secretase, presenilin-1,
and ADAM10. Many others possess potential calmodulin-binding domains that remain to be verified. Three calmodulin binding
proteins are associated with the formation of neurofibrillary tangles: two kinases (CaMKII, CDK5) and one protein phosphatase
(PP2B or calcineurin). Many of the genes recently identified by genome wide association studies and other studies encode
proteins that contain putative calmodulin-binding domains but only a couple (e.g., APOE, BIN1) have been experimentally
confirmed as calmodulin binding proteins. At least two receptors involved in calcium metabolism and linked to Alzheimer’s
disease (mAchR; NMDAR) have also been identified as calmodulin-binding proteins. In addition to this, many proteins that are
involved in other cellular events intimately associated with Alzheimer’s disease including calcium channel function, cholesterol
metabolism, neuroinflammation, endocytosis, cell cycle events, and apoptosis have been tentatively or experimentally verified
as calmodulin binding proteins. The use of calmodulin as a potential biomarker and as a therapeutic target is discussed.
Keywords: Alzheimer’s disease, calcium, calcium channels, calmodulin, calmodulin binding proteins, cholesterol metabolism,
endocytosis, genome wide association studies, neuroinflammation
INTRODUCTION
Alzheimer’s disease (AD) is the leading cause of
dementia, with close to 50 million people worldwide
currently suffering from dementia and the number
expected to increase to 1 in 85 people by the year 2050
[1]. First described by the German psychiatrist Alois
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3257; Fax: +1 905 828 3792; E-mail: danton.oday@utoronto.ca.
Alzheimer, it manifests through progressive memory
loss ultimately encompassing a loss of recognition
of people, places, and things, eventually leading to
death [2]. Currently, the cure for AD remains elusive,
with treatments focusing on managing symptoms and
attempts to slow neurodegeneration. While the initiat-
ing events leading to late onset AD (LOAD) remain
to be discovered, the formation of amyloid plaques
and neurofibrillary tangles remain as central culprits
in the neurodegenerative aspects of the disease. More
recently, numerous genes and several metabolic events
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Fig. 1. Calcium-bound calmodulin (CaM) and its calcium-free form (Apo-CaM) are involved to many central events linked to Alzheimer’s
disease as discussed in this review.
have been identified as either central or contributing
factors in AD.
A decade ago, O’Day and Myre [3] proposed the
“Calmodulin Hypothesis” as an extension of the well-
established “calcium hypothesis” of LOAD. In that
study, a number of proteins linked to the production
of amyloid- (A) were shown to possess putative
calmodulin binding domains (CaMBDs) suggesting
that they could be regulated by the small regu-
latory, calcium-binding protein calmodulin (CaM).
Subsequently, two of the central proteins in this
event, amyloid- precursor protein (APP) and beta-
secretase (BACE1; beta-site APP cleaving enzyme
1) were each shown to bind to and be regulated
by CaM [4, 5]. Non-amyloidogenic processing of
APP in platelets was induced in a time- and dose-
dependent manner by the calmodulin antagonist W7
[6]. Over the past 10 years, advancements have been
made into understanding the pathways involved in
both amyloid plaque and neurofibrillary tangle for-
mation. Based on these new insights, here we first
re-examine the role of calmodulin binding proteins
(CaMBPs) in the formation of the two primary cul-
prits linked to the symptoms and progression of AD:
amyloid plaques and neurofibrillary tangles (Fig. 1).
As summarized in Fig. 1, we then look at the func-
tion of calmodulin as a regulator of other events
and recently identified proteins linked to the dis-
ease before looking at CaM as a potential therapeutic
target.
THE CALCIUM HYPOTHESIS AND
CALMODULIN
The “calcium hypothesis” is one prominent model
for AD [7]. It suggests that an imbalance of cal-
cium levels in cells precedes the signaling pathway
malfunctions and neuronal deterioration observed in
neurodegenerative diseases. It has long been known
that calcium ions (Ca2+) play a substantial role in
normal physiology. In the brain, Ca2+ functions in neu-
rotransmitter synthesis and release as well as in the
control of membrane excitability [8]. The intracellu-
lar concentration of Ca2+ is kept within a tight range
of 10−7 to 10−8 mol; variation from the norm, even if
slight, is detrimental when it persists [8].
Calcium ions perform their function primarily
through binding to membrane or cytoplasmic proteins.
Arguably the primary calcium-binding protein and
effector of calcium function is the small protein CaM.
Highly conserved and ubiquitously expressed in all
eukaryotes and in all cell types, it is a member of
the EF-hand family of calcium sensors [9]. CaM
possesses four E-F hands, two at the C-terminal and
two at the N-terminal, allowing it to bind up to four
Ca2+ ions [9, 10]. Each lobe (N, C) can bind up to
two calcium ions (Fig. 2). The number and location
of binding of this cation affects CaM’s conforma-
tion and how it interacts with its target CaMBPs.
Proteins do not bind to Ca2+/CaM via traditional
targeting sequences. In the absence of Ca2+, the
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Fig. 2. Apo-Calmodulin (Apo-CaM) can bind up to two calcium ions in each of its N-term (pink) or C-term lobes (green). These binding options
affect the conformation of CaM and its ability to bind to specific target CaM-binding proteins.
apo-CaM conformation allows the binding of the
sub-group of Ca2+-independent CaMBPs (Table 1).
Ca2+-independent binding occurs via well-defined
IQ [(FILV)Qxxx(RK)Gxxx(RK)xx(FILVWY)] and
IQ-like [(FILV)Qxxx(RK)xxxxxxxx] motifs. Upon
Ca2+ binding, CaM undergoes significant conforma-
tional changes allowing it to bind to Ca2+-dependent
CaMBPs. Ca2+-dependent binding involves a diver-
sity of motifs and sub-classes that are defined
primarily by the sequence and positioning of
hydrophobic amino acids sometimes in conjunction
with basic residues within the motif (e.g., 1–5–10
motif: xxx(FILVW)xxxx(FAILVW)xxxx(FILVW)
where x = any a.a.) [11]. The “Calmodulin Target
Database” categorizes the various types of CaM-
binding motifs (Table 1; http://calcium.uhnres.
utoronto.ca/ctdb/ctdb/home.html). In addition to the
major CaMBD categories (e.g., 1–8–14, 1–5–10, etc.),
there are also a large number of others that do not fit
into any of these specific categories (e.g., 1–12 and
basic motifs) among other more recently discovered
binding non-canonical motifs [12].
To add to this non-conventional binding interaction,
Villarroel et al. [13] have presented evidence indicat-
ing that while CaM binds its calcium-dependent targets
via these CaMBDs in their normal orientation it can
also bind to those sequences in the opposite direction.
Furthermore, their data also suggests that upon bind-
ing to its target, CaM can undergo a conformational
rotation further altering its structural relationship with
that CaMBP. Considering the central importance of
CaM to essential life processes, this complex protein
interaction may be part of the reason CaM histori-
cally has eluded serving as a primary target in various
diseases. Once the interactions between CaM and spe-
cific CaMBPs linked to AD are fully clarified, it may
become possible to develop target-specific peptides to
fight different aspects of the disease.
CALMODULIN AND AMYLOID PLAQUE
FORMATION
The Calmodulin Target Database identifies the pres-
ence and types of CaMBDs in protein sequences with
over 90% accuracy [11]. Using this database, O’Day
and Myre [3] first identified a diversity of potential
CaMBPs linked to the formation of amyloid plaques.
The “amyloid hypothesis” is arguably the predom-
inant hypothesis for the symptoms and progression
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Table 1
Calmodulin binding domain (CaMBD) subclasses that have been identified and experimentally verified
of AD [14]. It is based on the aggregation of A
peptides plus a multitude of other components to
form extracellular amyloid plaques in the brains of
AD sufferers [15–17]. A peptides vary slightly in
length and are formed through the regulated intramem-
brane proteolytic (RIP) cleavage of APP at the
carboxy-terminal fragment (CTF) by -secretase and
-secretase enzymes (Fig. 3) [18]. The main products
of this pathway are A40 and A42 with A42 being
the more toxic fragment [19]. A peptides interfere
with normal signaling leading to neuronal malfunction
and, eventually, synapse loss [20]. On the other hand,
there exists a non-amyloidogenic pathway of cleav-
age, where APP is cleaved in the middle of the A
sequence by-secretase thereby preventing the forma-
tion of the neurodegenerative A peptide [18].
CaM is significantly decreased in the brains of AD
individuals [21]. In spite of this, the existing CaM can
interact with several proteins in the amyloid pathway.
Two independent groups have demonstrated experi-
mentally that APP binds to CaM [4, 6]. The main
-secretase enzyme in the brain that begins the amy-
loidogenic processing of APP is BACE1 (Fig. 3). Its
activity and expression are both increased in AD brains
and its ablation completely prevents APP cleavage
through the amyloidogenic pathway in mouse mod-
els [22, 23]. BACE1 cleaves APP at CTF-99 (and
sometimes CTF-89), as opposed to cleavage at CTF-83
which is observed in the non-amyloidogenic path-
way [18]. Most of the action of BACE1 on APP
occurs in endocytotic vesicles as opposed to when
APP is localized at the cell membrane [24]. BACE1
binds CaM with its activity being increased up to
2.5-fold by CaM in a dose dependent manner in
vitro [5]. Sequence analysis of the enzyme indicates
that binding most likely occurs via a 1-16 motif
((FILVW)xxxxxxxxxxxxxx(FILVW)).
After BACE1, -secretase performs the final cleav-
age to produce A. -Secretase consists of four main
subunits: nicastrin (Nic), anterior pharynx-defective 1
(APH-1), presenilin (PSEN), and presenilin enhancer
2 (PEN-2), which assemble in the order listed (Fig. 3)
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Fig. 3. Calmodulin binding proteins linked to the amyloidogenenic and non-amyloidogenic pathways. amyloid- precursor protein (APP);
anterior pharynx defective 1 (APH-1); site-amyloid converting enzyme 1 or-secretase (BACE1); A Disintegrin And Metalloproteinase Family
(ADAM 9,10,17, 19); endothelin-converting enzyme (ECE); insulin-degrading enzyme (IDE); nicastrin (Nic); presenilin enhancer protein 2
(PEN-2); and presenilin-1 (PSN-1); superscripts: ∗putative CaMBD detected; vCaMBD experimentally verified.
[25]. PEN-2, the final subunit to be attached, leads to
the activation of the enzyme complex [25]. Sequence
analysis of the four -secretase subunits using the
Calmodulin Database revealed that they all possess
presumptive CaMBDs, with some having more than
one binding motif [3]. Of these subunits, only PSEN
has been experimentally verified to bind CaM [26].
Michno et al. [26] also showed that the loss of func-
tion of a single CaM copy inhibits Ca2+ dysregulation
induced by PSEN in Drosophila neurons.
Several enzymes can degrade A including
neprilysin, endothelin-converting enzymes (ECE),
insulin degrading enzymes (IDE), and BACE1 (Fig. 3)
[18, 27]. Aside from BACE1, none of the other A
degrading enzymes have yet been experimentally con-
firmed to bind CaM, although all of them were found
to possess putative CaMBDs [28]. In addition to bind-
ing to the enzymes which generate A, CaM was
found to directly bind to A42 itself through a 1-8-
14 motif ((FILVW)xxxxxx(FAILVW)xxxxx(FILVW))
[29]. When bound to CaM, A cannot inhibit the brain
plasma membrane Ca2+-ATPase (PMCA) and prevent
Ca2+ entry into the cell. Thus the accumulated data
presents a clear link between amyloid plaque forma-
tion, Ca2+, and CaM revealing how the dysfunction
in Ca2+ levels and A production contribute to each
other with CaM functioning at many levels during this
interaction.
As mentioned above APP binds to CaM in
vitro in a Ca2+-independent manner [6]. The non-
amyloidogenic pathway involves -secretase cleavage
of APP at CTF-83 precluding the formation of A
(Fig. 3). APP processed in this non-amyloidogenic
pathway appears to have a neuroprotective effect. The
ADAM (A Disintegrin And Metalloproteinase) fam-
ily of proteases, specifically ADAM9, 10, 17, and
19 are all thought to exhibit -secretase activity in
neurons [18]. ADAM10, the predominant -secretase,
binds CaM through an IQ-motif [30–32]. In contrast,
ADAM17 does not bind CaM [30]. Importantly, W7
an antagonist of CaM stimulates cleavage of APP via
the non-amyloidogenic pathway [6, 33].
CALMODULIN AND NEUROFIBRILLARY
TANGLE FORMATION
Neurofibrillary tangles constitute the second major
hallmark of AD. Consisting primarily of hyperphos-
phorylated tau, they have long been known to be a
neuropathological feature of the disease; although their
role in neurodegeneration has come into question [34].
Tau belongs to the family of microtubule-associated
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Table 2
Putative calmodulin binding domain (CaMBD) classes in GWAS proteins linked to Alzheimer’s disease. Appropriate hydrophobic (green),
acidic (yellow), and IQ (cyan) amino acids are highlighted.
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Fig. 4. Calmodulin binding proteins linked to tau phosphorylation. Calmodulin-dependent kinase II (CaMKII); cyclin-dependent kinase 5
(CDK5); calmodulin (CaM); neurofibrillary tangles (NFTs); CDK5 activator (P35); protein phosphatase 2B (PP2B); colors: green, stimu-
lated/activated; red, inhibited.
proteins which function in microtubule assembly and
stability [35]. Several early studies provided evidence
for an in vitro association between tau and CaM that
is Ca2+ dependent (Fig. 4) [36–38]. Tau’s association
with CaM prevents its binding to microtubules [36].
Furthermore, tau cannot be phosphorylated by protein
kinase C in vitro when it is in a complex with CaM [37].
In spite of this extensive early association, no recent
studies have been conducted on the direct interaction
between CaM and tau.
Tau can undergo many post-translational mod-
ifications including phosphorylation, acetylation,
glycation, and oxidation [39]. Phosphorylation is the
best studied and important tau modification related
to AD, with several kinases and some phosphatases
working in concert to regulate phosphorylation at sev-
eral specific serine, threonine, and tyrosine residues
[39]. Of the kinases, two have been found to inter-
act with CaM: Ca2+/CaM-dependent protein kinase II
(CaMKII) and cyclin-dependent kinase 5 (CDK5). In
addition, protein phosphatase 2B (PP2B or calcineurin)
is a well-established CaMBP that has been historically
linked to tau dephosphorylation [40].
CaMKII phosphorylates tau in vitro at different sites
including Ser262 which is in the microtubule bind-
ing domain of tau (Fig. 3) [41–44]. The enzyme was
also found to phosphorylate tau in neurons at Ser416
[45]. CaM is responsible for activating CaMKII by
binding to its regulatory segment through a 1–5–10
binding motif [10, 46]. However, CaMKII is capable
of acquiring autonomy from CaM in the presence of
high frequency Ca-2+ spikes, despite it being able to
phosphorylate tau more efficiently in the presence of
CaM [43, 46].
It should also be noted that CaMKII has an estab-
lished role in neuronal apoptosis which is observed
throughout the course of the disease. Phosphorylation
by CaMKII is a central pro-apoptotic event. Normally
a murine double mutant 2 (MDM2) pathway mediates
the degradation of CaMKII but this process is defective
in AD lymphocytes [47]. The role of CaM in apoptosis
has been reviewed by Berchtold and Villalobo [48].
CDK5 is another kinase with a well-established role
in tau phosphorylation (Fig. 4). Various studies indicate
that it phosphorylates a number of specific residues
including Ser202, Thr205, Ser369, and others, both in
vitro and in vivo [49–53]. Additionally, reducing CDK5
activity using RNA interference was found to reduce
tau phosphorylation and the number of neurofibrillary
tangles formed in transgenic mouse models, making
it a possible target for AD treatment [54]. CDK5 has
several activators, one of which is p35 [50]. Truncation
of p35 into a shorter p25 fragment is observed in AD
[50]. Unlike p35, p25 leads to constitutive CDK5 acti-
vation [50, 53]. The p10 fragment lost from p35 upon
conversion to p25 is involved in the mutually exclu-
sive binding of p35 to microtubules or CDK5 [55, 56].
The p10 segment also facilitates Ca2+-dependent bind-
ing between p35 and CaM, which not observed with
p25 (Fig. 4) [55]. It is possible that p35 contains a
novel CaMBD since no canonical binding motifs were
identified upon sequence analysis of the p35 peptide
sequence [55]. Moreover, in the model organism Dic-
tyostelium discoideum, CDK5 itself was found to bind
CaM in a Ca2+-independent manner [57]. The two
CaMBDs found in D. discoideum CDK5 are highly
conserved in human CDK5 indicating that the same
interaction likely occurs in the human brain [57].
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The role of the well documented CaMBP PP2B
in tau dephosphorylation was established early but
recently has been relegated to a less important role
with the discovery of other phosphatases linked to the
process. More to the point, studies on the function
of PP2B in tau dephosphorylation have been con-
tradictory. PP2B is a heterodimer made of A and B
subunits. The A subunit is catalytic and known to
be activated by CaM in a Ca2+-dependent manner
through a 1–8–14 binding motif while the B sub-
unit is regulatory and is itself largely homologous
to CaM and able to bind Ca2+ ions [58, 59]. Early
studies in vitro showed PP2B’s ability to dephospho-
rylate tau at positions including Ser262 and Ser369
(Fig. 4) [60–62]. However, when compared to other
phosphatases such as protein phosphatase 2A (PP2A)
and protein phosphatase 1 (PP1), it was found that
PP2B is only responsible for 7% of the dephospho-
rylation activity which has been attributed to its low
affinity toward tau [63]. Recent studies have reported
an increased enzyme activity level of PP2B in AD
brains [63]. While this seems contradictory to previ-
ous findings, this increase was ascribed to the increased
levels of calpain I [64]. Calpain I is Ca2+ activated and
its activity is increased in AD brains. It cleaves the A
subunit of PP2B and renders it CaM-independent; the
truncated form of PP2B has higher activity than the full
length protein [64]. Therefore, the persistent high level
of phosphorylation observed should indicate that PP2B
does not play a major role in tau dephosphorylation.
On the other hand, in vivo studies using PP2B-specific
inhibitors resulted in hyperphosphorylated tau at posi-
tions including Ser262, Ser369, Thr181, and Thr231
[65–67]. To complicate matters further, CaM binding
to PP2B, which normally activates the enzyme, was
found to inhibit its association with tau [40].
CAMKII AND PP2B ARE INVOLVED IN
MEMORY STORAGE
Furthermore, the two enzymes CaMKII and PP2B
have been implicated as central players in defi-
cient memory storage that occurs due to the Ca2+
deregulation that occurs in AD individuals. These
enzymes often act antagonistically by phosphorylat-
ing (CaMKII) and dephosphorylating (PP2B) the same
proteins. Long-term potentiation (LTP) has been well
studied in the mammalian hippocampus as it is the
region of the brain that is critical in the formation
and retrieval of various forms of memory. The mor-
phology of hippocampal neurons including dendritic
spine structures and their density are essential for
memory storage. In the case of AD, progressive dam-
age to the hippocampus results in an inability to
form and store certain types of new memories con-
comitant with alterations in neuronal morphology,
dendritic spine density, synapse formation, and deficits
in LTP [68, 69]. Importantly, hyperactivation of the
Ca2+/CaM-dependent phosphatase calcineurin in the
hippocampus has been reported for various models of
AD and suggests that aberrant Ca2+ signaling con-
tributes to deregulated interactions between CaM and
calcineurin which impairs memory, increases tau phos-
phorylation and neuronal death [69, 70]. Short-term
inhibition of calcineurin using the inhibitor FK506
was found to effectively reverse object recognition
deficits in Tg2576 mice and improved dendritic spine
loss, neuronal structure, and morphology in plaque
bearing YFP-APP/PS1 transgenic mice [71]. Other
work further demonstrated a direct connection between
CaMKII activity in spines and spine loss in AD and
aging brains [72]. Taken together, these data strongly
suggest that the inhibition of calcineurin might pro-
tect hippocampal neurons and that the mechanism by
which this occurs should be explored further. Recently,
Berridge [73] has reviewed the positive role of CaMKII
in memory formation and of PP2B in memory era-
sure. He has presented evidence arguing that the rapid
memory erasure that occurs during wakefulness in AD
individuals due to the action of PP2B prevents the abil-
ity of consolidating these memories during sleep which
occurs in those not suffering from the disease. While
much remains to be learned about this model, this again
puts CaM and two of its primary targets—CaMKII and
PP2B—at the center of issues facing those suffering
from AD.
CAM AND THE ACETYLCHOLINE
RECEPTOR
The oldest of all the models attempting to explain
the causes and effects of AD, the “cholinergic hypoth-
esis” is based on the decrease in acetylcholine
neurocommunication [74, 75]. In AD, the levels
of acetylcholine, acetylcholine receptors (AchR),
and cholinergic neurons decrease [76]. Acetyl-
choline activates either inotropic nicotinic (nAchR)
or metabotropic muscarinic (mAchR) receptors. The
five subtypes (M1-M5) of mAchR are G-protein cou-
pled receptors (GPCR) involved in Ca2+ signaling.
M1 mAchR has been a primary therapeutic focus in
the treatment of AD [77]. Like a number of verified
GPCRs, M1 mAchR has a CaMBD on the cytoplasmic
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i3 loop [78]. Peptides derived from this intracellular
loop bind to CaM. To date these peptides have not been
used therapeutically. It should be noted that CaM also
has indirect but major effects on the function of the
mAchR first through regulation via phosphorylation
(CaMKII) and dephosphorylation (PP2B) and second
through more complex processes such as the formation
of multiprotein complexes including the binding and
activation of TRPC6 channels that are also involved in
Ca2+ signaling [79].
NMDAR, A CALMODULIN-BINDING
RECEPTOR
The N-methyl-D-aspartate receptor (NMDAR) is a
major Ca2+ channel involved in synaptic plasticity
and memory [80, 81]. The receptor binds glutamate
allowing cations to enter the cell [80]. NMDAR lev-
els are generally reduced in AD, likely as an adaptive
mechanism in response to the increased receptor activ-
ity due to Ca2+ dysregulation [82]. Likewise, A
can cause overactivation of the receptor leading to
increased intracellular Ca2+ levels, an effect which can
be reduced through NMDAR antagonists [83]. In addi-
tion to affecting Ca2+ homeostasis, NMDAR plays a
role in the cell’s antioxidant response, where it can aug-
ment the cell’s defenses under conditions of oxidative
stress [84]. On the other hand, overstimulation of the
receptor can also lead to free radical generation which
can be detrimental [85].
NMDAR is a heteromultimeric complex with the
required presence of at least one monomer of each of
NR1 and NR2. Different combinations of NR1 splice
products and NR2 subunits vary among different cell
types offering the receptor varied pharmacological and
physiological properties [81]. CaM is capable of bind-
ing the NR1 subunit both in vitro and in vivo [86–88].
Binding occurs at two locations, both of which are in
the cytoplasmic domain of NR1, reducing the mean
time of the channel being open and the frequency at
which it opens thus inhibiting Ca2+ entry [81]. While
its specific regulatory role is being elucidated, Apo-
CaM can associate with the NR1 subunit at a different
site than Ca2+ dependent CaM binding. Upon Ca2+
entry activated Ca2+/CaM induces a rapid structural
shift in the NMDAR allowing for an efficient negative
feedback cycle [89]. Binding of NR1 to CaM occurs
through a novel 1–7 motif which is highly unusual and
only observed in myristoylated alanine-rich C-kinase
substrate (MARCKS) [90].
OTHER ROLES FOR CALMODULIN IN
ALZHEIMER’S DISEASE
Recent genome wide association studies (GWAS)
have linked certain gene polymorphisms with LOAD
[91–94]. Although the specific functions of each gene
and its encoded protein remain to be elucidated, most
are involved either in cholesterol metabolism, neuroin-
flammation or endocytosis [95]. Using the Calmodulin
Target Database, the proteins discussed below were
found to be putative CaMBPs but most remain to be
experimentally verified (Table 2).
Cholesterol metabolism
The brain is rich in cholesterol, containing approx-
imately 25% of the body’s cholesterol content which
is essential for myelin formation [96]. An association
between cholesterol and AD was made when statins,
which are used to treat elevated cholesterol levels, were
found to reduce disease incidence [97]. Furthermore,
levels of 24S-hydroxycholesterol, one of the first inter-
mediates of cholesterol elimination, were higher in AD
individuals than in healthy controls [98]. Since it can-
not cross the blood-brain barrier, the brain’s cholesterol
is internally synthesized and must be shuttled around
by lipoproteins containing ApoE [96, 99]. ApoE con-
tains two putative CaMBDs each with 2-3 potential
binding motifs (Table 2). While the role of CaM bind-
ing in ApoE function remains to be clarified, it is well
established that the ApoE4 variant is a significant risk
factor for LOAD.
Clusterin (CLU) and ATP-binding cassette trans-
porter A7 (ABCA7) are two other proteins involved in
cholesterol metabolism with polymorphisms which are
risk factors for LOAD [91–93]. Each possesses a sin-
gle putative CaMBD as revealed through Calmodulin
Target Database analysis (Table 2). The CLU protein
is multifunctional affecting immunity and apoptosis
in addition to playing a role in lipid metabolism [100].
With its expression increased in AD, CLU (also termed
apolipoprotein J) is a component of the lipid parti-
cles that transport cholesterol [101]. ABCA7 belongs
to the ABC transporter superfamily, which regulates
cholesterol transport across the cell membrane [102].
However, it is likely that the highly homologous pro-
tein ABCA1, which is a proven CaMBP, plays a more
prominent role in this process than ABCA7, according
to mouse models. Binding through a 1–5–8–14 motif,
CaM affects the stability of ABCA1 in vivo, preventing
its degradation [103].
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Neuroinﬂammation
Inflammation of neurons and dysregulation of differ-
ent aspects of the immune response are characteristic
of AD brains (reviewed in [104]). GWAS identified
several proteins that affect the immune response. All
were found through the Calmodulin Target Database
to contain presumptive CaMBDs, although none have
so far been experimentally tested to confirm the inter-
action with CaM (Table 2). Cluster of differentiation
33 (CD33), which is upregulated in microglial cells of
AD brains, impairs A clearance propagating plaque
pathology [91, 105]. A second protein, the comple-
ment receptor 1 (Cr1) connects the complement system
and CaM to AD although its exact role in prop-
agation of pathology remains unknown [91, 106].
Moreover, polymorphisms in the membrane span-
ning 4-subfamily A (MS4A) proteins, MS4A4E and
MS4A6A, were also found as risk factors for LOAD
[91]. The function of the MS4A family remains poorly
characterized, although, they may be components of
Ca2+ channels and thus, affect Ca2+ homeostasis in
neurons [107].
AβPP endocytosis
The APP protein is synthesized in the rough
endoplasmic reticulum and travels through the trans-
Golgi network to the cell membrane where it can be
brought back into the cell through receptor-mediated
endocytosis [108]. The exact subcellular location
where A is generated remains a topic of debate
although endocytotic vesicles seem to be likely can-
didates since inhibition of endocytosis reduces the
levels of A produced [109]. A number of puta-
tive CaMBPs related to vesicle assembly were also
identified including the phosphatidylinositol-binding
clathrin assembly protein (PICALM), the scaffold-
ing protein CD2-associated protein (CD2AP), the
sortilin-related receptor L (SORL1), ephrin type-
A receptor 1 (EPHA1), and the bridging integrator
1 (BIN1) (Table 2) [28]. To date, only BIN1
has been experimentally confirmed as a CaMBP
[110].
AD, calmodulin, and the cell cycle
Although the amyloid cascade hypothesis dominates
the AD research landscape, a number of alternative the-
ories have been suggested in attempts to understand the
pathogenesis of AD. In the developing brain neurons
are integrated into complex synaptic networks after
they have completed their proliferation, migration, and
differentiation. The cellular signals that tightly regu-
late neuronal connectivity and plasticity also serve to
ensure neurons are maintained in a differentiated state
while simultaneously preventing reactivation of signal-
ing pathways that control proliferation and cell cycle
progression. The protection from aberrant neuronal
cell cycle re-entry occurs through strict regulatory
mechanisms at specific cell cycle control checkpoints.
However, neuronal plasticity and formation of neuritic
extensions allows for progression of the cycle early
in G1 phase which is followed by opposing signals
for re-differentiation back into G0. The mechanisms
controlling transient re-entry into the cell cycle is con-
sidered to be an essential event for synaptic remodeling
(reviewed in [111]).
In AD, the G1/S phase check-point regulatory mech-
anisms break down to the point where individual
neurons can proceed through S-phase and undergo full
or partial DNA re-replication with consequent entry
into the G2 phase of the cell cycle [112–114]. Nor-
mally, in cycling non-neuronal cells, the G2 phase
prepares the cell for mitosis, but in the case of post-
mitotic neurons, improper cycling halts during the
G2 phase and triggers neuronal death by apopto-
sis. Evidence from a number of animal models of
human neurodegenerative disorders strongly suggests
that atypical cell cycle re-entry events precede neuronal
apoptosis ultimately leading to cell death [114–117].
Upregulation or improper protein degradation alters
the normal level of a number of cell cycle proteins,
including proliferating cell nuclear antigen (PCNA),
cyclin D1, CDK4, and cyclin B1, within the hip-
pocampus and other AD-diseased brain regions. These
markers of cell cycle re-entry are not found randomly
dispersed throughout the AD diseased brain nor are
they detected in age-matched control patient brains
[118, 119]. This ectopic cell cycle re-entry (CCR) is
believed to account for a significant fraction of cor-
tical neurons that are lost in AD [120]. Even more
intriguing is that cell cycle markers are not only
one of the earliest cellular abnormalities detected in
AD, but theoretically may contribute to AD pathol-
ogy including tau phosphorylation, A formation, and
neuronal calcium-ion dysfunction [121–123]. Seward
et al. [124] further showed that CCR requires solu-
ble A, tau, and concomitant activation of kinases
including the Ca2+-calmodulin kinase II (CaMKII).
This irregular cell cycle control within specific neu-
ronal populations in the AD brain likely plays an early,
yet crucial role for abnormalities associated with AD
pathogenesis [117, 125, 126].
D.H. O’Day et al. / Calmodulin and Alzheimer’s Disease 563
Studies in many cell types using a variety of
approaches have implicated both Ca2+ and CaM as
key regulators of distinct checkpoints in the cell cycle,
including early G1, the G1 to S phase transition and
G2/M transition. Calmodulin interactions with the
CaMK family of CaMBPs act as important regulators
of cell cycle progression (reviewed in [128]). Putative
CaM-binding motifs have also been detected in a large
number of cell cycle proteins including the cyclins
(reviewed in [129]). Mitogenic stimulation leads to a
variety of Ca2+-CaM-mediated responses yet when the
stimulation is permanent it causes changes in the sub-
cellular distribution of CaM, which leads to changes
in the total amount of CaM, alters cellular sensitivity
to Ca2+ signals, and presents the potential for aber-
rant interactions between CaM and CaMBPs [130].
Although the deregulation of Ca2+/calmodulin signal-
ing in AD brains is not well understood, increased
levels of CaM and decreased levels of phosphorylated
CaMKII have been reported in the hippocampus of
APP/PS1 mice [131]. These changes might be reflec-
tive of an aberrant involvement of CaM/CaMKII in the
impairment of cell cycle control in AD. Indeed many
different kinds of signaling pathways are changed in
AD, and the relevance of the mitogenic upregulation
that may induce cell cycle re-entry in the disease
process is far from clear. Future studies will need
to focus on identifying the mechanisms that regulate
CaM and CaMKII expression in the hippocampus, as
well as the downstream effector molecules involved, as
this will potentially uncover new pathways for under-
standing the dysregulation of cell cycle control in AD
brains.
CALMODULIN AS A BIOMARKER
Since AD cannot be fully verified until autopsy,
the search for minimally invasive biomarkers for the
disease continues [132]. While cerebrospinal levels
of A, tau, and phosphorylated tau are effective
biomarkers, this approach is fairly invasive and not
without problems. Generally blood tests for those same
biomarkers have been less than rewarding. Esteras et al.
[133] have shown that levels of CaM are significantly
increased in lymphoblasts from AD individuals. In a
subsequent study, the increased CaM levels in lym-
phoblasts and peripheral blood mononuclear cells from
AD individuals were found to be significantly greater
than from non-dementia persons or those suffering
from other types of dementia including amyotrophic
lateral sclerosis, dementia with Lewy bodies, and
frontotemporal dementi, among others [134]. These
results suggest that CaM levels in peripheral blood
cells have the potential to serve as a biomarker
for various dementias including that resulting
from AD.
CONCLUSION
Considering the multiple regulatory functions that
CaM carries out in all cells, it is not surprising that it
has many links to the underlying events of AD. CaM is
involved in the defining aspects of AD progression and
pathogenesis including A generation, tau phospho-
rylation, Ca2+ homeostasis, cholesterol metabolism,
neuroinflammation, APP endocytosis, and apoptosis.
While it seems to present itself as a primary tar-
get in combating the symptoms and progression of
the disease, many issues appear to reduce its current
appeal as a therapeutic target. It has both positive and
negative regulatory roles, making blanket inhibition
approaches untenable. Thus currently available phar-
maceutically proven CaM antagonists likely would not
be an option for medical treatment. However, circum-
stances could change with the development of new
CaM antagonists (e.g., [135]). Since most CaMBPs
bind to CaM in unique ways and since some have
multiple types of binding sequences, based on the
technologies that exist for developing CaM antago-
nists it should be possible to develop target-specific
pharmaceuticals.
The idea of targeting CaM and its CaMBPs is not
without precedent. CaM is already a potential tar-
get for the treatment of Huntington’s disease, another
neurodegenerative disease. Huntington’s disease is an
autosomal dominant disorder due to a polyglutamine
expansion in the huntingtin protein that is exacer-
bated by transglutaminase [136]. Huntingtin binds
CaM and this binding can be disrupted using a CaM-
peptide consisting of amino acids 76–121 of the
CaM protein [137]. This peptide was then shown to
reduce the level of transglutaminase-modified hunt-
ingtin and cytotoxicity in differentiated neuroblastoma
(SH-SY5Y) cells. Subsequent treatment of a Hunting-
ton’s mouse (R6/2) model with this CaM-peptide led to
neuroprotection via the mechanisms established in the
tissue culture cells [138]. Thus CaM-Huntingtin bind-
ing appears to present a potential therapeutic target
in combating this disease. The identification of crit-
ical CaMBPs linked to AD may also open a similar
door.
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